Onychomycosis Treatment Market Trends, Growth Report To 2024-2033

The onychomycosis treatment global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

 

Onychomycosis Treatment Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

 

Market Size –

The onychomycosis treatment market size has grown strongly in recent years. It will grow from $3.39 billion in 2023 to $3.65 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing fungal infections, aging population, public awareness, rising prevalence of onychomycosis, rising disposable incomes.

 

The onychomycosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.73 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to aging population, telemedicine expansion, combination therapies, increasing access to healthcare, changing lifestyles and environmental factors, increasing prevalence of diabetes. Major trends in the forecast period include dermatological advancements, drug delivery innovations, personalized treatment plans, topical treatment advances, digital health solutions, laser therapy.

 

Order your report now for swift delivery @

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

 

Scope Of Onychomycosis Treatment Market

The Business Research Company’s reports encompass a wide range of information, including:

  1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
  2. Drivers: Examination of the key factors propelling market growth.
  3. Trends: Identification of emerging trends and patterns shaping the market landscape.
  4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
  5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
  6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

 

Onychomycosis Treatment Market Overview

Market Drivers –

The increasing number of fungal infections is expected to propel the growth of the onychomycosis treatment market going forward. Fungal infections are microbial diseases caused by various fungi, affecting different body parts or causing specific conditions. Onychomycosis (a fungal nail infection) is typically treated with oral antifungal medications or topical antifungal solutions to eliminate the underlying fungal growth and restore healthy nail growth. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2021, 3,270 clinical cases and 7413 screening cases of C. auris were recorded in the United States. Furthermore, in March 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the total number of deaths from fungal infections increased from 5,922 in 2020 to 7,199 in 2021. Therefore, the increasing number of fungal infections is driving the growth of the onychomycosis treatment market.

 

Market Trends –

Major companies operating in the onychomycosis treatment market are focused on developing new products, such as MOB-015 and getting them approved by federal agencies to gain a competitive edge in the market. For instance, in June 2023, Moberg Pharma AB, a Sweden-based pharmaceutical company, received approval for MOB-015 in the European Union for treating mild to moderate fungal infections of the nails in adults. The European Union’s approval marks the innovative onychomycosis medication’s first global marketing authorization. Two Phase 3 trials supporting MOB-015’s approval demonstrated improved mycological cure (76% vs. up to 42% for comparators) and a much greater total cure rate than the vehicle, all without experiencing any serious adverse effects. The topical terbinafine formulation MOB-015 allows effective terbinafine concentrations to reach the nail and nail bed without the risk of systemic exposure associated with oral terbinafine treatment.

 

The onychomycosis treatment market covered in this report is segmented –

1) By Type: Distal Sublingual Onychomycosis; White Superficial Onychomycosis; Proximal Sublingual Onychomycosis; Candida Onychomycosis; Other Types

2) By Treatment Type: Drugs; Laser Therapy; Photodynamic Therapy

3) By Age Group: 0 To 18 Years; 18 To 39 Years; 40 To 64 Years; 65 Years And Above

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

 

Get an inside scoop of the onychomycosis treatment market, Request now for Sample Report @

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

 

Regional Insights –

North America was the largest region in the onychomycosis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

 

Key Companies

Major players in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

 

Table of Contents

  1. Executive Summary
  2. Onychomycosis Treatment Market Report Structure
  3. Onychomycosis Treatment Market Trends And Strategies
  4. Onychomycosis Treatment Market – Macro Economic Scenario
  5. Onychomycosis Treatment Market Size And Growth

…..

  1. Onychomycosis Treatment Market Competitor Landscape And Company Profiles
  2. Key Mergers And Acquisitions
  3. Future Outlook and Potential Analysis
  4. Appendix

 

Learn About Us:

The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

 

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Leave a Reply

Your email address will not be published. Required fields are marked *